Efficacy and safety of sofosbuvir/belpatasvir combination tablets for patients infected with pan-genotypic hepatitis C virus

Efficacy and safety of sofosbuvir/belpatasvir combination tablets for patients infected with pan-genotypic hepatitis C virus - Sofosbuvir/velpatasvir therapy for patients with HCV

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035625

Enrollment

Registered

2019-01-23

Start date

2019-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic liver disease infected with HCV

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients infected with HCV

Exclusion criteria

Exclusion criteria: 1) Patients who do not have consent to clinical research 2) Patietns accompanying HCC 2) Patients with pregnancy

Design outcomes

Primary

Measure	Time frame
Rates of Sustained virological response at 12 and 24 weeks after the end of treatment	—

Countries

Japan

Contacts

Public ContactUchida Yoshihito

Saitama Medical University Department of Gastroenterology & Hepatology

y_uchida@saitama-med.ac.jp049-276-1198

Outcome results